<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-96985</identifier>
<setSpec>1575-0922</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">The new antidiabetic agents in the firing line.... safety reasons or witch hunt?</dc:title>
<dc:creator>Masmiquel Comas, Lluís</dc:creator>
<dc:creator>Nicolau Ramis, Joana</dc:creator>
<dc:language>es</dc:language>
<dc:source>Endocrinol Nutr;59(1): 1-8, ene. 2012.</dc:source>
<dc:identifier>ibc-96985</dc:identifier>
<dc:title xml:lang="es">Los nuevos antidiabéticos en el punto de mira&#133; ¿razones de seguridad o caza de brujas?</dc:title>
<dc:subject>^d29633</dc:subject>
<dc:subject>^d3946^s22057</dc:subject>
<dc:subject>^d28612</dc:subject>
<dc:subject>^d7182^s22079</dc:subject>
<dc:subject>^d52846^s22063</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d9562^s22036</dc:subject>
<dc:subject>^d50914^s22006</dc:subject>
<dc:subject>^d50567^s32387</dc:subject>
<dc:subject>^d7124^s22054</dc:subject>
<dc:subject>^d2359^s22054</dc:subject>
<dc:subject>^d8862^s22079</dc:subject>
<dc:subject>^d24613^s22079</dc:subject>
<dc:subject>^d38089^s22020</dc:subject>
<dc:type>article</dc:type>
<dc:date>201201</dc:date>
</metadata>
</record>
</ibecs-document>
